CG Oncology Q4 2024 Earnings Report

CG Oncology EPS Results

• Actual EPS: -$0.48
• Consensus EPS: -$0.37
• Beat/Miss: Missed by -$0.11
• One Year Ago EPS: N/A

CG Oncology Revenue Results

• Actual Revenue: $0.46 million
• Expected Revenue: $0.11 million
• Beat/Miss: Beat by +$353.00 thousand
• YoY Revenue Growth: N/A

CG Oncology Announcement Details

• Quarter: Q4 2024
• Date: 3/25/2025
• Time: Before Market Opens
• Conference Call Date: Friday, March 28, 2025
• Conference Call Time: 7:00AM ET

CG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biotechnology company dedicated to the development of next-generation immuno-oncology therapies. The company’s core focus lies in leveraging novel oncolytic viral platforms and targeted immunomodulatory agents to activate the body’s immune system against solid tumors. Its lead candidate, CG0070, is an oncolytic adenovirus engineered to selectively replicate within and destroy bladder cancer cells while stimulating a localized immune response via granulocyte-macrophage colony-stimulating factor (GM‐CSF).

In addition to its oncolytic virus pipeline, CG Oncology is advancing a proprietary immunomodulator licensed from European collaborators. This fusion protein is designed to bind tumor-associated superantigens and activate tumor-infiltrating T cells, broadening the company’s reach into multiple oncology indications. Together, these assets reflect a diversified strategy aimed at both direct tumor eradication and systemic immune activation.

The company conducts multi-center clinical trials across North America and Europe, collaborating with leading academic institutions and contract research organizations to evaluate safety and efficacy in patients with advanced cancers. CG Oncology’s global approach enables rapid patient enrollment and regulatory engagement, positioning its candidates for potential registration in key markets.

Founded in the early 2010s as a spinout focusing on oncolytic viral research, CG Oncology has grown under the leadership of an experienced management team with deep roots in biotechnology and pharmaceutical development. Supported by a board of directors with expertise spanning immunology, virology and oncology drug commercialization, the company continues to pursue strategic partnerships and funding opportunities to advance its pipeline toward commercialization.